Vinorelbine liposomal - Taiwan Liposome Company

Drug Profile

Vinorelbine liposomal - Taiwan Liposome Company

Alternative Names: Nanoliposomal vinorelbine - Taiwan Liposomal Company; TLC-178; Vinorelbine encapsulated liposome - TLC

Latest Information Update: 29 Oct 2016

Price : $50

At a glance

  • Originator Taiwan Liposome Company
  • Class Antineoplastics; Small molecules; Vinca alkaloids
  • Mechanism of Action Mitosis inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - T cell lymphoma
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Non-Hodgkin's lymphoma; Solid tumours

Most Recent Events

  • 19 Oct 2016 Vinorelbine liposomal - Taiwan Liposome Company receives Orphan Drug status for T-cell lymphoma in USA
  • 03 Oct 2016 Preclinical trials in Solid tumours in Taiwan (Parenteral)
  • 03 Oct 2016 US FDA grants an IND approval for Advanced Solid tumours and lymphomas in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top